The Cambridge Phenomenon:Solexa, Genome Sequencing

ViaCyte, Stem Cells for Diabetes

John WestCEO, ViaCyte, Inc

Previously CEO, Solexa

1The Cambridge Phenomenon Conference, Oct 5, 2010

Solexa Technology FlowReagents, Instruments, Software, Sequences

2The Cambridge Phenomenon Conference, Oct 5, 2010

Just a few of the UK team...

3The Cambridge Phenomenon Conference, Oct 5, 2010

SG CowenInvestment bankers New York

Solexa, Little ChesterfordEssex

FinancingIn 2005, once Solexa became a US Nasdaq-listed company, it raised $97.5M in 8 months.

4The Cambridge Phenomenon Conference, Oct 5, 2010

5The Cambridge Phenomenon Conference, Oct 5, 2010

6The Cambridge Phenomenon Conference, Oct 5, 2010

...said Mr. West..."By sequencing a family of at least four we can ... interpret compound heterozygote variations in genes - those cases where multiple variations in a single gene, but on opposing chromosome copies, combine as a virtual homozygote. I expect that these are much more prevalent, and the source of much more phenotypic variability, than previously understood. Working with medical geneticists, we look forward to exploring this new visibility into factors influencing our future health."

7The Cambridge Phenomenon Conference, Oct 5, 2010

The Cambridge Phenomenon Conference, Oct 5, 2010

8

3.5 M SNPs (350k novel)

9,707 non-synonymoous SNPs per HPGP

2,428 trait-associated loci per HPGP report (1,716 unique)

GET-Evidence

(28)

OMIM (99)

HuGENet GWAS (1,133)

SNPedia (326)

HGMD (282)

Pharm GKB (28)

Other Hypotheses

(532)

Genome Analysis Summary to Date

John West

9/30/2010

2 loci in same drug metabolism gene re Nexium:Slow metaboliser

Ultra Fast MetabolizerAlso compound heterozygocity

Factor 5 Leiden &

Compound heterozygocity

Associated trait description includes

“diabetes” (95)

Type 1 (48)

Type 2 (45)

Diabetes non-specific (2)

.....

9The Cambridge Phenomenon Conference, Oct 5, 2010

10The Cambridge Phenomenon Conference, Oct 5, 2010

Market Scale Anecdotes

11The Cambridge Phenomenon Conference, Oct 5, 2010

Projected Adoption of Genome-Scale DNA sequencing

• Approx. 30 – 50 named individuals sequenced so far• A few research-clinical cases have saved lives, esp in cancer• Current capacity based on installed base of Illumina instruments

is 25 – 50,000 complete human genomes per year• Source of the gap:

– Research human genome sequencing is much larger– Many other research uses of DNA sequencing capacity– Price still falling: $2,000 by late 2011 ?

• Medical interpretation improving & action-ability transitioning:– Statistical association (probabilities of future disease)– Mechanism of action– Intervention to prevent or better treat

• Potential for ethical issues declines as this transition is made

12The Cambridge Phenomenon Conference, Oct 5, 2010

Stem Cell-Derived Therapy for Diabetes

13The Cambridge Phenomenon Conference, Oct 5, 2010

Financing Development of Stem Cell Derived Therapies

• Technology risk declining, but regulatory timing risk remains a challenge for investors & pharma

– Geron on clinical hold for almost 2 years– US Federal Government policy adds to perception of risk

• California Institute of Regenerative Medicine (CIRM) as a model for funding (aka Proposition 71):

– ViaCyte awarded $26M – of the scale needed for a major development– Additional $25M possible for clinical trials– Most CIRM funding has gone to universities

• Cost of initial developments are only affordable for major medical reimbursement categories, or for springboards to them

14The Cambridge Phenomenon Conference, Oct 5, 2010

Thank-you for your attention

John WestViaCyte, Inc

jwest@viacyte.com

+1 858 455 3677

15The Cambridge Phenomenon Conference, Oct 5, 2010